KYMR: Kymera Therapeutics Inc

46.18 USD 0.56 (1.20%)

Secteur: Soins de Santé Base: US Dollar Devise de profit: US Dollar

Le taux de change de KYMR a changé de -1.20% aujourd'hui. Au cours de la journée, l'instrument a été échangé à un minimum de 46.00 et à un maximum de 47.30.

Suivez la dynamique Kymera Therapeutics Inc. Les cotations en temps réel vous aideront à réagir rapidement aux changements du marché. En basculant entre différentes périodes, vous pouvez surveiller les tendances et la dynamique des taux de change par minutes, heures, jours, semaines et mois. Utilisez ces informations pour prévoir les changements du marché et prendre des décisions de trading éclairées.

Graphique en Plein Ecran

KYMR Nouvelles

Zacks 13:54 Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock?
Benzinga 12:14 Synovus Financial, Gilead Sciences And More On CNBC's 'Final Trades' - iShares U.S. Financial ETF (ARCA:IYF), Gilead Sciences (NASDAQ:GILD)
Investing 12:55 Kymera Therapeutics stock price target lowered to $65 at Brookline Capital
Investing 08:52 Morgan Stanley initiates Kymera Therapeutics stock with Overweight rating
Investing 07:57 Kymera Therapeutics Q4 2024 slides: immunology pipeline advances with $600M cash infusion
Investing 13:00 Tuesday’s Insider Activity: Major Buys and Sells Shake Up Markets
Investing 22:46 Kymera Therapeutics (KYMR) director group buys $13.9 million in stock
Investing 13:00 Monday’s Insider Activity: Top Buys and Sells in US Stocks
Investing 00:18 Kymera Therapeutics: Baker Bros acquire $28.8m in shares
Investing 14:23 Kymera price target raised to $54 from $51 at BofA on pipeline updates
Investing 13:49 Kymera’s partnerships with Sanofi and Gilead drive value
Investing 04:08 Kymera Therapeutics Announces Pricing of $250 Million Public Offering
Benzinga 13:11 Tesla To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Thursday - Apple (NASDAQ:AAPL), Alnylam Pharmaceuticals (NASDAQ:ALNY)
Investing 12:37 Kymera stock price target raised to $60 from $54 at H.C. Wainwright
Investing 20:52 Kymera Therapeutics price target lowered to $70 at Brookline Capital
Investing 20:17 Kymera Therapeutics launches $250 million public stock offering
Investing 20:13 Kymera Therapeutics stock falls after announcing $250 million offering
Investing 17:30 Kymera stock falls as Jefferies lowers price target on program shifts
Seeking Alpha 17:09 Kymera Shrugs Off Sanofi Bust With Gilead Deal - But There Are Caveats (NASDAQ:KYMR)
Investing 14:09 Kymera stock falls as Sanofi drops IRAK4 degrader for next-gen candidate
Benzinga 13:23 Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapies - Gilead Sciences (NASDAQ:GILD), Sanofi (NASDAQ:SNY)
Investing 11:17 Sanofi to advance Kymera’s oral IRAK4 degrader KT-485 to clinical testing
Seeking Alpha 01:14 Tracking Baker Brothers Portfolio – Q1 2025 Update
Investing 21:55 Kymera at Goldman Sachs Conference: Pioneering Oral Protein Degraders

Range quotidien

46.00 47.30

Range Annuel

19.44 53.27

Clôture Précédente: 46.35
Ouverture: 46.74

Bid: 46.18
Ask: 46.48

Plus Bas: 46.00
Plus Haut: 47.30

Volume: 1.161 K

Changement quotidien: -1.20%
Changement Mensuel: 2.58%

Changement à 6 Mois: 20.89%
Changement Annuel: -0.86%

19 juillet, samedi